• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconClinical trials

Clinical trials

Dr. Shiv Rao speaks
Startups & VentureAbridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it
By Lily Mae LazarusJune 11, 2026
Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study
HealthZepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study
By Jonel Aleccia and The Associated PressMay 12, 2025
A woman wearing a head wrap gets a vaccine from a masked doctor
HealthEarly mRNA vaccine trial results show potential breakthrough in fighting one of the deadliest cancers
By Beth GreenfieldFebruary 27, 2025
Cancer vaccination, conceptual illustration
HealthPersonalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
By Lindsey LeakeFebruary 7, 2025
A young woman undergoes a brain scan.
HealthMeet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
By Lindsey LeakeFebruary 6, 2025
Close-up view of man in blue button-down shirt placing pills in his hand.
HealthNew pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids
By Bloomberg and Gerry SmithJanuary 31, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
HealthHate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Moderna is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403.
HealthModerna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
By Lindsey LeakeJanuary 11, 2025
Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.
HealthMerck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
By Lindsey LeakeDecember 20, 2024
Merck snags Chinese obesity drug in nearly $2 billion deal
TechMerck snags Chinese obesity drug in nearly $2 billion deal
By Robert Langreth and BloombergDecember 18, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
HealthZepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
By Lindsey LeakeDecember 4, 2024
Health care CFOs look beyond cutting costs to juice profitability 
NewslettersHealth care CFOs look beyond cutting costs to juice profitability 
By Sheryl EstradaJuly 26, 2024
Saundra Pelletier, CEO of Evofem Biosciences.
MagazineBirth control fail: Why American women can’t have better contraceptives in 2023
By Maria AspanApril 5, 2023
Medical doctor giving injection to make antibody for coronavirus
HealthThe business of clinical trials is booming. Private equity has taken notice
By Rachana Pradhan and Kaiser Health NewsDecember 2, 2022
People walk by Pfizer building in NYC
HealthPfizer pauses clinical trials in Russia, says it will continue to send drugs to patients
By Riley Griffin and BloombergMarch 14, 2022
1
  • 1
  • 2
  • 3
  • 4
4
Most Popular
Personal Finance
Current price of oil as of June 15, 2026placeholder alt text
By Joseph HostetlerJune 15, 2026
Personal Finance
Current price of silver as of Monday, June 15, 2026placeholder alt text
By Joseph HostetlerJune 15, 2026
Success
Team USA star Ricardo Pepi grew up in a trailer in El Paso—and his parents pawned their car title to fuel his soccer dream. Now, he’s in the World Cupplaceholder alt text
By Preston ForeJune 15, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.